237 related articles for article (PubMed ID: 24709254)
1. Identification of AP80978, a novel small-molecule inhibitor of hepatitis C virus replication that targets NS4B.
Dufner-Beattie J; O'Guin A; O'Guin S; Briley A; Wang B; Balsarotti J; Roth R; Starkey G; Slomczynska U; Noueiry A; Olivo PD; Rice CM
Antimicrob Agents Chemother; 2014 Jun; 58(6):3399-410. PubMed ID: 24709254
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization and In Vivo Efficacy of GSK8853, a Small-Molecule Inhibitor of the Hepatitis C Virus NS4B Protein.
Pouliot JJ; Thomson M; Xie M; Horton J; Johnson J; Krull D; Mathis A; Morikawa Y; Parks D; Peterson R; Shimada T; Thomas E; Vamathevan J; Van Horn S; Xiong Z; Hamatake R; Peat AJ
Antimicrob Agents Chemother; 2015 Oct; 59(10):6539-50. PubMed ID: 26259798
[TBL] [Abstract][Full Text] [Related]
3. Resistance analysis and characterization of NITD008 as an adenosine analog inhibitor against hepatitis C virus.
Qing J; Luo R; Wang Y; Nong J; Wu M; Shao Y; Tang R; Yu X; Yin Z; Sun Y
Antiviral Res; 2016 Feb; 126():43-54. PubMed ID: 26724382
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic analyses of hepatitis C virus variants observed in clinical studies of VX-222, a nonnucleoside NS5B polymerase inhibitor.
Jiang M; Zhang EZ; Ardzinski A; Tigges A; Davis A; Sullivan JC; Nelson M; Spanks J; Dorrian J; Nicolas O; Bartels DJ; Rao BG; Rijnbrand R; Kieffer TL
Antimicrob Agents Chemother; 2014 Sep; 58(9):5456-65. PubMed ID: 24982088
[TBL] [Abstract][Full Text] [Related]
5. Discovery of 2-(4-sulfonamidophenyl)-indole 3-carboxamides as potent and selective inhibitors with broad hepatitis C virus genotype activity targeting HCV NS4B.
Zhang N; Turpoff A; Zhang X; Huang S; Liu Y; Almstead N; Njoroge FG; Gu Z; Graci J; Jung SP; Pichardo J; Colacino J; Lahser F; Ingravallo P; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2016 Jan; 26(2):594-601. PubMed ID: 26652483
[TBL] [Abstract][Full Text] [Related]
6. In vitro efficacy of approved and experimental antivirals against novel genotype 3 hepatitis C virus subgenomic replicons.
Yu M; Corsa AC; Xu S; Peng B; Gong R; Lee YJ; Chan K; Mo H; Delaney W; Cheng G
Antiviral Res; 2013 Nov; 100(2):439-45. PubMed ID: 24013001
[TBL] [Abstract][Full Text] [Related]
7. Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from
Sahuc ME; Sahli R; Rivière C; Pène V; Lavie M; Vandeputte A; Brodin P; Rosenberg AR; Dubuisson J; Ksouri R; Rouillé Y; Sahpaz S; Séron K
J Virol; 2019 May; 93(10):. PubMed ID: 30842319
[TBL] [Abstract][Full Text] [Related]
8. Development and characterization of a replicon-based phenotypic assay for assessing HCV NS4B from clinical isolates.
Rajyaguru S; Yang H; Martin R; Miller MD; Mo H
Antiviral Res; 2013 Nov; 100(2):328-36. PubMed ID: 24013002
[TBL] [Abstract][Full Text] [Related]
9.
Ng TI; Krishnan P; Pilot-Matias T; Kati W; Schnell G; Beyer J; Reisch T; Lu L; Dekhtyar T; Irvin M; Tripathi R; Maring C; Randolph JT; Wagner R; Collins C
Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193664
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus.
Bilello JP; Lallos LB; McCarville JF; La Colla M; Serra I; Chapron C; Gillum JM; Pierra C; Standring DN; Seifer M
Antimicrob Agents Chemother; 2014 Aug; 58(8):4431-42. PubMed ID: 24867983
[TBL] [Abstract][Full Text] [Related]
11. PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication.
Lam AM; Murakami E; Espiritu C; Steuer HM; Niu C; Keilman M; Bao H; Zennou V; Bourne N; Julander JG; Morrey JD; Smee DF; Frick DN; Heck JA; Wang P; Nagarathnam D; Ross BS; Sofia MJ; Otto MJ; Furman PA
Antimicrob Agents Chemother; 2010 Aug; 54(8):3187-96. PubMed ID: 20516278
[TBL] [Abstract][Full Text] [Related]
12. Screening of hepatitis C virus inhibitors using genotype 1a HCV replicon cell lines.
Robinson M; Tian Y; Pagratis N; Delaney WE
Curr Protoc Microbiol; 2011 Aug; Chapter 17():Unit17.7. PubMed ID: 21805689
[TBL] [Abstract][Full Text] [Related]
13. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.
Lenz O; Verbinnen T; Lin TI; Vijgen L; Cummings MD; Lindberg J; Berke JM; Dehertogh P; Fransen E; Scholliers A; Vermeiren K; Ivens T; Raboisson P; Edlund M; Storm S; Vrang L; de Kock H; Fanning GC; Simmen KA
Antimicrob Agents Chemother; 2010 May; 54(5):1878-87. PubMed ID: 20176898
[TBL] [Abstract][Full Text] [Related]
14. HCV NS5A replication complex inhibitors. Part 4. Optimization for genotype 1a replicon inhibitory activity.
St Laurent DR; Serrano-Wu MH; Belema M; Ding M; Fang H; Gao M; Goodrich JT; Krause RG; Lemm JA; Liu M; Lopez OD; Nguyen VN; Nower PT; O'Boyle DR; Pearce BC; Romine JL; Valera L; Sun JH; Wang YK; Yang F; Yang X; Meanwell NA; Snyder LB
J Med Chem; 2014 Mar; 57(5):1976-94. PubMed ID: 23573957
[TBL] [Abstract][Full Text] [Related]
15. In vitro characterization of GSK2485852, a novel hepatitis C virus polymerase inhibitor.
Voitenleitner C; Crosby R; Walker J; Remlinger K; Vamathevan J; Wang A; You S; Johnson J; Woldu E; Van Horn S; Horton J; Creech K; Shotwell JB; Hong Z; Hamatake R
Antimicrob Agents Chemother; 2013 Nov; 57(11):5216-24. PubMed ID: 23939896
[TBL] [Abstract][Full Text] [Related]
16. Novel hepatitis C virus reporter replicon cell lines enable efficient antiviral screening against genotype 1a.
Robinson M; Yang H; Sun SC; Peng B; Tian Y; Pagratis N; Greenstein AE; Delaney WE
Antimicrob Agents Chemother; 2010 Aug; 54(8):3099-106. PubMed ID: 20516274
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel HCV inhibitors: synthesis and biological activity of 6-(indol-2-yl)pyridine-3-sulfonamides targeting hepatitis C virus NS4B.
Zhang X; Zhang N; Chen G; Turpoff A; Ren H; Takasugi J; Morrill C; Zhu J; Li C; Lennox W; Paget S; Liu Y; Almstead N; Njoroge FG; Gu Z; Komatsu T; Clausen V; Espiritu C; Graci J; Colacino J; Lahser F; Risher N; Weetall M; Nomeir A; Karp GM
Bioorg Med Chem Lett; 2013 Jul; 23(13):3947-53. PubMed ID: 23683597
[TBL] [Abstract][Full Text] [Related]
18. PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally.
Graci JD; Jung SP; Pichardo J; Lahser F; Tong X; Gu Z; Colacino JM
Antimicrob Agents Chemother; 2016 Dec; 60(12):7060-7066. PubMed ID: 27620477
[TBL] [Abstract][Full Text] [Related]
19. Chemical genetics-based discovery of indole derivatives as HCV NS5B polymerase inhibitors.
Jin G; Lee S; Choi M; Son S; Kim GW; Oh JW; Lee C; Lee K
Eur J Med Chem; 2014 Mar; 75():413-25. PubMed ID: 24561671
[TBL] [Abstract][Full Text] [Related]
20. Selected replicon variants with low-level in vitro resistance to the hepatitis C virus NS5B polymerase inhibitor PSI-6130 lack cross-resistance with R1479.
Ali S; Leveque V; Le Pogam S; Ma H; Philipp F; Inocencio N; Smith M; Alker A; Kang H; Najera I; Klumpp K; Symons J; Cammack N; Jiang WR
Antimicrob Agents Chemother; 2008 Dec; 52(12):4356-69. PubMed ID: 18838588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]